RU2009100159A - Тиенопирамидины, полезные в качестве модуляторов ионных каналов - Google Patents
Тиенопирамидины, полезные в качестве модуляторов ионных каналов Download PDFInfo
- Publication number
- RU2009100159A RU2009100159A RU2009100159/15A RU2009100159A RU2009100159A RU 2009100159 A RU2009100159 A RU 2009100159A RU 2009100159/15 A RU2009100159/15 A RU 2009100159/15A RU 2009100159 A RU2009100159 A RU 2009100159A RU 2009100159 A RU2009100159 A RU 2009100159A
- Authority
- RU
- Russia
- Prior art keywords
- pain
- ring
- cor
- con
- independently
- Prior art date
Links
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 39
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 31
- 239000001257 hydrogen Substances 0.000 claims abstract 31
- 229910052736 halogen Inorganic materials 0.000 claims abstract 30
- 150000001875 compounds Chemical class 0.000 claims abstract 27
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 24
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 22
- 125000005842 heteroatom Chemical group 0.000 claims abstract 20
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 19
- 229910052760 oxygen Chemical group 0.000 claims abstract 19
- 239000001301 oxygen Chemical group 0.000 claims abstract 19
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 19
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 19
- 239000011593 sulfur Chemical group 0.000 claims abstract 19
- 150000002367 halogens Chemical class 0.000 claims abstract 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 13
- 125000005843 halogen group Chemical group 0.000 claims abstract 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 8
- 229910052799 carbon Inorganic materials 0.000 claims abstract 8
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 3
- 208000002193 Pain Diseases 0.000 claims 43
- 230000036407 pain Effects 0.000 claims 34
- 125000004093 cyano group Chemical group *C#N 0.000 claims 31
- 125000002619 bicyclic group Chemical group 0.000 claims 13
- 208000004296 neuralgia Diseases 0.000 claims 9
- 230000001154 acute effect Effects 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- -1 4-substituted piperidine ring Chemical group 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 208000005298 acute pain Diseases 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 230000002981 neuropathic effect Effects 0.000 claims 4
- 208000009935 visceral pain Diseases 0.000 claims 4
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 claims 3
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 claims 3
- 208000008035 Back Pain Diseases 0.000 claims 3
- 208000006561 Cluster Headache Diseases 0.000 claims 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 3
- 201000007100 Pharyngitis Diseases 0.000 claims 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 230000009172 bursting Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 208000007914 Labor Pain Diseases 0.000 claims 2
- 208000035945 Labour pain Diseases 0.000 claims 2
- 208000008930 Low Back Pain Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 206010061533 Myotonia Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 206010059604 Radicular pain Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000001037 epileptic effect Effects 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000015706 neuroendocrine disease Diseases 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 210000003497 sciatic nerve Anatomy 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010000087 Abdominal pain upper Diseases 0.000 claims 1
- 208000002485 Adiposis dolorosa Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000001375 Facial Neuralgia Diseases 0.000 claims 1
- 206010016059 Facial pain Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 206010046555 Urinary retention Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000028659 discharge Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000011384 erythromelalgia Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000004885 piperazines Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000001738 temporomandibular joint Anatomy 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical group C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 125000001118 alkylidene group Chemical group 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 0 C*C(*)(*)CC(NC*(C)C1(C)C(*)C1)O Chemical compound C*C(*)(*)CC(NC*(C)C1(C)C(*)C1)O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81276506P | 2006-06-12 | 2006-06-12 | |
| US60/812,765 | 2006-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009100159A true RU2009100159A (ru) | 2010-07-20 |
Family
ID=38828498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009100159/15A RU2009100159A (ru) | 2006-06-12 | 2007-06-12 | Тиенопирамидины, полезные в качестве модуляторов ионных каналов |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8883781B2 (enExample) |
| EP (1) | EP2043654A2 (enExample) |
| JP (1) | JP2009539988A (enExample) |
| KR (1) | KR20090021218A (enExample) |
| CN (1) | CN101500575A (enExample) |
| AU (1) | AU2007258313A1 (enExample) |
| CA (1) | CA2654842A1 (enExample) |
| IL (1) | IL195861A0 (enExample) |
| MX (1) | MX2008015908A (enExample) |
| NO (1) | NO20090157L (enExample) |
| RU (1) | RU2009100159A (enExample) |
| WO (1) | WO2007146284A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005003632A1 (de) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Katheter für die transvaskuläre Implantation von Herzklappenprothesen |
| US8052750B2 (en) | 2006-09-19 | 2011-11-08 | Medtronic Ventor Technologies Ltd | Valve prosthesis fixation techniques using sandwiching |
| US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
| ES2903231T3 (es) | 2008-02-26 | 2022-03-31 | Jenavalve Tech Inc | Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente |
| US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
| SMT201700456T1 (it) * | 2009-07-27 | 2017-11-15 | Gilead Sciences Inc | Composti eterociclici fusi come modulatori dei canali ionici |
| US10856978B2 (en) | 2010-05-20 | 2020-12-08 | Jenavalve Technology, Inc. | Catheter system |
| CA2799459A1 (en) | 2010-05-25 | 2011-12-01 | Jenavalve Technology Inc. | Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent |
| JP5858586B2 (ja) | 2010-07-02 | 2016-02-10 | ギリアード サイエンシーズ， インコーポレイテッド | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
| TW201219401A (en) * | 2010-09-14 | 2012-05-16 | Lexicon Pharmaceuticals Inc | Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use |
| GB201105659D0 (en) | 2011-04-01 | 2011-05-18 | Xention Ltd | Compounds |
| TWI577670B (zh) | 2011-05-10 | 2017-04-11 | 基利科學股份有限公司 | 充當離子通道調節劑之稠合雜環化合物 |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| GB201114212D0 (en) * | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| AR090037A1 (es) * | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| WO2015028209A1 (en) | 2013-08-30 | 2015-03-05 | Jenavalve Technology Gmbh | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
| WO2016150806A1 (en) | 2015-03-20 | 2016-09-29 | Jenavalve Technology, Inc. | Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath |
| EP3288495B1 (en) | 2015-05-01 | 2019-09-25 | JenaValve Technology, Inc. | Device with reduced pacemaker rate in heart valve replacement |
| US10221191B2 (en) | 2015-12-22 | 2019-03-05 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| JP7081749B2 (ja) | 2016-05-13 | 2022-06-07 | イエナバルブ テクノロジー インク | 心臓弁プロテーゼ送達システム |
| CN109862893B (zh) * | 2016-11-07 | 2023-02-17 | 范德比尔特大学 | 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂 |
| US11008335B2 (en) * | 2016-11-07 | 2021-05-18 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| WO2018138658A1 (en) | 2017-01-27 | 2018-08-02 | Jenavalve Technology, Inc. | Heart valve mimicry |
| JP7514005B2 (ja) | 2017-06-21 | 2024-07-10 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物 |
| EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2024102411A1 (en) | 2022-11-09 | 2024-05-16 | Jenavalve Technology, Inc. | Catheter system for sequential deployment of an expandable implant |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2133815A1 (en) * | 1993-10-12 | 1995-04-13 | Jeffrey Alan Dodge | Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| WO2001083456A1 (en) * | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Condensed heteroaryl derivatives |
| ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| MXPA06000051A (es) * | 2003-07-02 | 2006-03-21 | Vertex Pharma | Pirimidinas utiles como moduladores de canales ionicos dependientes de voltaje. |
| EP1663994B1 (en) * | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels |
| CN101068794B (zh) * | 2004-09-02 | 2012-12-19 | 沃泰克斯药物股份有限公司 | 可用作离子通道调控剂的喹唑啉 |
| EP1806347A4 (en) * | 2004-10-08 | 2009-07-01 | Astellas Pharma Inc | PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING |
| US7666901B2 (en) * | 2004-10-13 | 2010-02-23 | Wyeth | Analogs of 17-hydroxywortmannin as PI3K inhibitors |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
-
2007
- 2007-06-12 JP JP2009515453A patent/JP2009539988A/ja active Pending
- 2007-06-12 EP EP07796018A patent/EP2043654A2/en not_active Withdrawn
- 2007-06-12 US US11/811,909 patent/US8883781B2/en active Active
- 2007-06-12 WO PCT/US2007/013776 patent/WO2007146284A2/en not_active Ceased
- 2007-06-12 CN CNA2007800297622A patent/CN101500575A/zh active Pending
- 2007-06-12 RU RU2009100159/15A patent/RU2009100159A/ru not_active Application Discontinuation
- 2007-06-12 CA CA002654842A patent/CA2654842A1/en not_active Abandoned
- 2007-06-12 AU AU2007258313A patent/AU2007258313A1/en not_active Abandoned
- 2007-06-12 KR KR1020097000621A patent/KR20090021218A/ko not_active Withdrawn
- 2007-06-12 MX MX2008015908A patent/MX2008015908A/es unknown
-
2008
- 2008-12-11 IL IL195861A patent/IL195861A0/en unknown
-
2009
- 2009-01-12 NO NO20090157A patent/NO20090157L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009539988A (ja) | 2009-11-19 |
| AU2007258313A1 (en) | 2007-12-21 |
| US8883781B2 (en) | 2014-11-11 |
| CA2654842A1 (en) | 2007-12-21 |
| MX2008015908A (es) | 2009-01-28 |
| CN101500575A (zh) | 2009-08-05 |
| EP2043654A2 (en) | 2009-04-08 |
| NO20090157L (no) | 2009-01-12 |
| WO2007146284A3 (en) | 2008-04-03 |
| IL195861A0 (en) | 2009-09-01 |
| US20070287717A1 (en) | 2007-12-13 |
| KR20090021218A (ko) | 2009-02-27 |
| WO2007146284A2 (en) | 2007-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009100159A (ru) | Тиенопирамидины, полезные в качестве модуляторов ионных каналов | |
| JP2009539988A5 (enExample) | ||
| RU2011103451A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| JP2011526919A5 (enExample) | ||
| RU2007111897A (ru) | Хиназолины, полезные в качестве модуляторов ионных каналов перекрестные ссылки на родственные заявки | |
| JP5699152B2 (ja) | リジン特異的デメチラーゼ−１阻害剤およびその使用 | |
| JP2010539244A5 (enExample) | ||
| JP2011503112A5 (enExample) | ||
| JP2010528035A5 (enExample) | ||
| CA2497868A1 (en) | Heterocyclic compounds | |
| RU2010123876A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| AR035775A1 (es) | Compuestos derivados de quinazolin-4-ona y benzo[1,2,4]tiadiazina-1,1-dióxido, su uso, un proceso para su obtencion y composiciones farmaceuticas que los contienen | |
| MXPA04009784A (es) | Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas. | |
| EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
| JP2014504642A5 (enExample) | ||
| EA200200509A1 (ru) | Новые производные бензоимидазола, используемые в качестве антипролиферативного средства | |
| WO2006038112A1 (en) | Use of kinase inhibitors to promote neochondrogenesis | |
| KR20140006768A (ko) | Lsd1의 아릴사이클로프로필아민 기반 디메틸라아제 억제제 및 이의 의학적 이용 | |
| NO20072116L (no) | Farmasoytiske forbindelser | |
| TW200621249A (en) | Substituted amide beta secretase inhibitors | |
| MY147588A (en) | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives | |
| ES2617878T3 (es) | Inhibidores de tubulina basados en la pirazina | |
| CA2841452A1 (en) | Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use | |
| FR2804113A1 (fr) | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique | |
| CN109627186B (zh) | 氨基羰基氨基甲酸酯化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100615 |